MedTrace Logo

Canadian Hemophilia Prophylaxis Study

NCT01085344 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2019-12-05

Study results available
· View outcomes & findings →

Summary

Primary prophylaxis given less frequently initially, with the infusion frequency increased if needed (Escalating Dose Prophylaxis), is likely to be less expensive and associated with fewer complications than standard prophylaxis while reducing disability to a greater degree than intermittent therapy.

Conditions

  • Severe Hemophilia A

Interventions

BIOLOGICAL

Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)

escalating dose prophylaxis

BIOLOGICAL

Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)

escalating dose

Sponsors & Collaborators

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Brian M Feldman, MD · The Hospital for Sick Children

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Months
Max Age
30 Months
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-06-26
Primary Completion
2012-12-31
Completion
2014-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01085344 on ClinicalTrials.gov